Ichnos Glenmark Innovation subsidiary IGI Therapeutics has signed an exclusive licensing agreement with AbbVie for ISB 2001, ...

It is the second licensing deal that AbbVie has negotiated this year for a trispecific for multiple myeloma, coming in the ...

The antibody, ISB 2001, is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) ...

AbbVie (ABBV) and IGI Therapeutics SA have entered into an exclusive licensing agreement for the latter’s lead ...

But now, an Indian company has delivered a promising innovative anti-cancer drug molecule to deep-pocketed Big Pharma for ...

AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...

Chairman and Managing Director Glenn Saldanha said on Monday that the company has several assets under development, including ...

A Financial District-based drug discovery company inked a $1 billion licensing agreement with pharmaceutical giant AbbVie to ...

Nearly six years after Ichnos Sciences Inc. launched operations, a subsidiary of the now-named Ichnos Glenmark Innovation ...

AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody Jul. 10, 2025 7:30 AM ET AbbVie Inc ...

AbbVie has entered into a $1 billion licensing agreement with IGI Therapeutics SA, for IGI's lead investigational drug for ...

AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase ...